Welcome to our dedicated page for Nuvo Pharmaceuticals news (Ticker: MRVFF), a resource for investors and traders seeking the latest updates and insights on Nuvo Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvo Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvo Pharmaceuticals's position in the market.
On April 21, 2021, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX: MRV, OTCQX: MRVFF) announced the filing of a final base shelf prospectus, allowing for future securities offerings of up to C$40,000,000 over a period of 25 months. This move aims to enhance financial flexibility, enabling the company to issue various securities, including common shares and debt securities, as needed. Although the prospectus is in place, there is no guarantee of any securities being sold.
Miravo Healthcare (TSX:MRV, OTCQX:MRVFF) is set to present at the Planet MicroCap Showcase: VIRTUAL on April 22, 2021, at 10:00 a.m. EST. The presentation will be led by President & CEO Jesse Ledger and CFO Mary-Jane Burkett. Investors can access the live discussion via a provided webcast link. Additionally, 1on1 investor meetings can be booked for private discussions. Miravo specializes in healthcare products targeting diverse therapeutic areas and aims to grow through in-licensing and acquisitions. More details can be found on their website.
Miravo Healthcare, a Canadian-focused healthcare company, will present at two upcoming investor conferences. Jesse Ledger, President & CEO, and Mary-Jane Burkett, CFO, will represent the company. The first presentation is at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 10:00 a.m. EST. The second is at the Planet MicroCap Showcase on April 22, 2021, also at 10:00 a.m. EST. Miravo offers a diversified product portfolio targeting various therapeutic areas like pain, allergy, and neurology.
Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) announced that Jesse Ledger, President & Chief Financial Officer, will participate in the Q1 Virtual Investor Summit.
The event is scheduled for March 23-25, 2021, with Ledger's presentation set for March 24 at 3:30 PM ET. The Investor Summit aims to connect small cap and micro cap companies with investors, featuring 100 companies and over 300 investors. For registration, visit www.investorsummitgroup.com.
On March 11, 2021, Nuvo Pharmaceuticals Inc. (OTCQX: MRVFF) announced that its President & CEO, Jesse Ledger, and Interim CFO, Kelly Demerino, will present at the Q1 Virtual Investor Summit on March 24, 2021, at 3:30 p.m. EST. The Investor Summit aims to connect smallcap and microcap companies with investors, featuring over 100 companies and 300 investors. Miravo, operating from Mississauga, Ontario, focuses on healthcare products targeting various therapeutic areas and adheres to strict GMP regulations.
Miravo Healthcare (MRVFF) filed a preliminary base shelf prospectus across Canadian provinces to enhance financial flexibility. This prospectus allows the company to issue securities worth up to C$40 million over a 25-month period. The company can offer common shares, preferred shares, debt securities, and more, contingent on filing prospectus supplements. While the prospectus aims to provide strategic flexibility, there is no guarantee that securities will be sold. The company cannot initiate sales until receiving final receipts from regulators, also noting the securities cannot be offered in the U.S. without proper registration.
Nuvo Pharmaceuticals, operating as Miravo Healthcare, reported its financial results for FY 2020, showing adjusted total revenue of $71.0 million, down 5% compared to 2019.
Adjusted EBITDA grew by 4% to $28.4 million, despite a 12% drop in quarterly revenue to $17.3 million.
Key products, Blexten and Cambia, saw prescription increases of 35% and 17% respectively. The company has adapted operations due to COVID-19 and anticipates ongoing impacts on revenue timing.
Miravo Healthcare has announced an exclusive license and supply agreement with The Mentholatum Company for the commercialization of the Resultz formula in the U.S. Resultz, a Class 1 medical device approved by the FDA, targets the head lice treatment market, valued at over US$125 million. The commercial launch is anticipated for Summer 2021. The agreement is set for 18 months, allowing reassessment of market dynamics impacted by COVID-19. Miravo will supply finished products to Mentholatum, leveraging its established brand for market entry.
Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF), operating as Miravo Healthcare, announced the upcoming release of its fourth quarter 2020 financial results on March 8, 2021, before market opening. A conference call is scheduled for the same day at 11:00 a.m. ET, hosted by CEO Jesse Ledger and senior management, including a Q&A session. The company's portfolio includes products in various therapeutic areas, and its facilities comply with GMP regulations.